Contact Number:
Email:
Lewis graduated from Newcastle University in 2010 with a BSc in Biochemistry with Immunology. He then completed a PhD in Molecular Biology at The Babraham Institute, focussing on the role of post-transcriptional regulation on the development of the immune system, before embarking on a postdoctoral research project at Cambridge University to investigate the dynamics of signalling in early T cell development.
Lewis joined Sagittarius IP in 2017 based in our Cambridge office and qualified as a UK Chartered Patent Attorney and European Patent Attorney in 2021. He gained the Intellectual Property Litigation Certificate in 2022, and also holds the Certificate in IP Law from Queen Mary, University of London.
Lewis’ practice includes drafting, filing and prosecuting patent applications in the biotechnology and life sciences fields, and he coordinates the prosecution of a number of large IP portfolios around the world. He has particular experience and expertise in the fields of monoclonal antibodies and fragments, peptide-based therapies and delivery systems, cell therapy (e.g. chimeric antigen receptor T cells – CAR-T cells), gene therapy (e.g. using viral vectors), cell reprogramming methods (e.g. to pluripotent iPSCs), cell and organoid culture methods, and molecular analysis methods (e.g. sequencing).
Lewis has experience with invention spotting, patentability and freedom to operate and opposition work, and has previously worked at a major pharmaceutical firm on secondment where he gained further valuable experience working in an in-house environment. His current clients range from university/research institute tech transfer offices and new spin out companies to medium and large biotech companies with molecules in active clinical development.
He is also an editor for the European Patents Handbook.
Contact Number:
Email:
Lewis graduated from Newcastle University in 2010 with a BSc in Biochemistry with Immunology. He then completed a PhD in Molecular Biology at The Babraham Institute, focussing on the role of post-transcriptional regulation on the development of the immune system, before embarking on a postdoctoral research project at Cambridge University to investigate the dynamics of signalling in early T cell development.
Lewis joined Sagittarius IP in 2017 based in our Cambridge office and qualified as a UK Chartered Patent Attorney and European Patent Attorney in 2021. He gained the Intellectual Property Litigation Certificate in 2022, and also holds the Certificate in IP Law from Queen Mary, University of London.
Lewis’ practice includes drafting, filing and prosecuting patent applications in the biotechnology and life sciences fields, and he coordinates the prosecution of a number of large IP portfolios around the world. He has particular experience and expertise in the fields of monoclonal antibodies and fragments, peptide-based therapies and delivery systems, cell therapy (e.g. chimeric antigen receptor T cells – CAR-T cells), gene therapy (e.g. using viral vectors), cell reprogramming methods (e.g. to pluripotent iPSCs), cell and organoid culture methods, and molecular analysis methods (e.g. sequencing).
Lewis has experience with invention spotting, patentability and freedom to operate and opposition work, and has previously worked at a major pharmaceutical firm on secondment where he gained further valuable experience working in an in-house environment. His current clients range from university/research institute tech transfer offices and new spin out companies to medium and large biotech companies with molecules in active clinical development.
He is also an editor for the European Patents Handbook.
Lewis graduated from Newcastle University in 2010 with a BSc in Biochemistry with Immunology. He then completed a PhD in Molecular Biology at The Babraham Institute, focussing on the role of post-transcriptional regulation on the development of the immune system, before embarking on a postdoctoral research project at Cambridge University to investigate the dynamics of signalling in early T cell development.
Lewis joined Sagittarius IP in 2017 based in our Cambridge office and qualified as a UK Chartered Patent Attorney and European Patent Attorney in 2021. He gained the Intellectual Property Litigation Certificate in 2022, and also holds the Certificate in IP Law from Queen Mary, University of London.
Lewis’ practice includes drafting, filing and prosecuting patent applications in the biotechnology and life sciences fields, and he coordinates the prosecution of a number of large IP portfolios around the world. He has particular experience and expertise in the fields of monoclonal antibodies and fragments, peptide-based therapies and delivery systems, cell therapy (e.g. chimeric antigen receptor T cells – CAR-T cells), gene therapy (e.g. using viral vectors), cell reprogramming methods (e.g. to pluripotent iPSCs), cell and organoid culture methods, and molecular analysis methods (e.g. sequencing).
Lewis has experience with invention spotting, patentability and freedom to operate and opposition work, and has previously worked at a major pharmaceutical firm on secondment where he gained further valuable experience working in an in-house environment. His current clients range from university/research institute tech transfer offices and new spin out companies to medium and large biotech companies with molecules in active clinical development.
He is also an editor for the European Patents Handbook.
Lewis graduated from Newcastle University in 2010 with a BSc in Biochemistry with Immunology. He then completed a PhD in Molecular Biology at The Babraham Institute, focussing on the role of post-transcriptional regulation on the development of the immune system, before embarking on a postdoctoral research project at Cambridge University to investigate the dynamics of signalling in early T cell development.
Lewis joined Sagittarius IP in 2017 based in our Cambridge office and qualified as a UK Chartered Patent Attorney and European Patent Attorney in 2021. He gained the Intellectual Property Litigation Certificate in 2022, and also holds the Certificate in IP Law from Queen Mary, University of London.
Lewis’ practice includes drafting, filing and prosecuting patent applications in the biotechnology and life sciences fields, and he coordinates the prosecution of a number of large IP portfolios around the world. He has particular experience and expertise in the fields of monoclonal antibodies and fragments, peptide-based therapies and delivery systems, cell therapy (e.g. chimeric antigen receptor T cells – CAR-T cells), gene therapy (e.g. using viral vectors), cell reprogramming methods (e.g. to pluripotent iPSCs), cell and organoid culture methods, and molecular analysis methods (e.g. sequencing).
Lewis has experience with invention spotting, patentability and freedom to operate and opposition work, and has previously worked at a major pharmaceutical firm on secondment where he gained further valuable experience working in an in-house environment. His current clients range from university/research institute tech transfer offices and new spin out companies to medium and large biotech companies with molecules in active clinical development.
He is also an editor for the European Patents Handbook.
